Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Amendment No. 6 to Schedule 13D reports ownership and transfer details for DR REDDY'S LABORATORIES LTD ADSs (ticker RDY). On September 17, 2025, G.V. Prasad transferred 96,095,920 post-split shares to GVP Family Trust and K. Satish Reddy transferred 75,630,620 post-split shares to VSD Family Trust for estate planning and family succession. After these transfers, reporting persons may be deemed to beneficially own between approximately 9.07% and 13.58% of outstanding post-split shares depending on constructive ownership through trusts and HUFs. The filing explains source of shares (merger-related distributions, prior transfers, inheritance) and trust deeds that include ROFR and tag-along rights.